

SELECTED BIBLIOGRAPHY

THYMOSIN ALPHA 1 USE IN HIV INFECTION

Nonclinical Studies:

- A. Sztejn, M.B., et al. (1987) *In vitro* effects of thymosin and lithium on lymphoproliferative responses of normal donors and HIV seropositive male homosexuals with Aids-related complex. *Clinical Immunology and Immunopathology* **44**: 51-62.
- B. Sztejn, M. and Serrate, S. (1989) *Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes*. *International Journal of Immunopharmacology* **11**: 789-800.
- C. D'Agostini, C., et al. (1996) *Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus*. *International Journal of Immunopharmacology* **18**: 95-102.
- D. Baumann, C., et al. (1997) *Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways*. *Mechanisms of Ageing and Development* **94**: 85-101.
- E. College, D., et al. (1997) *Antiviral effect of thymosin alpha 1 versus leucocytic interferon in primary cultures of duck hepatocytes persistently infected with duck HBV in vitro*. *Second International Conference on Therapies for Viral Hepatitis*.
- F. Palamara, A., et al. (1998) *Thymosin alpha 1 inhibits sendai virus replication: involvement of intracellular redox state*. *6th International Expert Forum of Immunotherapy and Gene Therapy*.
- G. Knutsen, A.P., et al. (1999) *Thymosin alpha 1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model*. *International Journal of Immunopharmacology* **21**: 15-26.

Clinical Studies:

- H. Schulof, R., et al. (1986) *Phase I/II trial of thymosin fraction 5 and thymosin alpha 1 in HTLV-III seropositive subjects*. *Journal of Biological Response Modifiers* **5**: 429-443.

- I. Garaci, E., et al. (1992) *Combined therapy with zidovudine - thymosin alpha 1 - alpha interferon in the treatment of HIV-infected patients*. Second International Symposium on Combination Therapies.
- J. Garaci, E., et al. (1994) *Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection*. International Journal of Clinical Laboratory Research **24**: 23-28.
- K. Rasi, V., et al. (1995) *Influence of different medical treatments of HIV-related noninfectious retinopathy*. Annals of Ophthalmology **27**:178-183.
- L. Ramachandran, R., et al. (1996) *Polyethylene glycol-modified interleukin-2 and thymosin alpha 1, in human immunodeficiency virus type 1 infection*. Journal of Infectious Diseases **173**: 1005-1008.
- M. Garaci, E., et al. (1996) *Efficacy and safety of combined therapy with zidovudine (AZT), alpha-interferon (IFNA) and thymosin alpha 1 (TA1) in HIV infected people*. 11th International Conference on AIDS.
- N. Garaci, E., et al. (1998) *A randomized controlled study for the evaluation of the activity of a triple combination of zidovudine, thymosin alpha 1, and interferon alpha in HIV-infected individuals with CD4 counts between 200 and 500 cells/mm³*. Antiviral Therapy **3**: 103-111.
- O. Chadwick, D. et al. (2003) *A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy*. Clinical Experimental Immunology **134**: 477-481.